By FieldPulse Staff · March 22, 2026
Tags: oncology, m-and-a, novartis, breast-cancer
Novartis is acquiring Synnovation Therapeutics for $2B upfront and up to $3B total to gain SNV4818, a next-generation PI3Kα inhibitor in Phase 1/2 for HR+/HER2- breast cancer — a direct upgrade on its own approved drug Piqray.
Novartis announced on March 19-20, 2026 it will acquire the Pikavation Therapeutics business unit of Synnovation Therapeutics in a deal valued at $2 billion upfront with up to $1 billion in additional milestone payments. The asset is SNV4818, a pan-mutant selective PI3Kα inhibitor currently in Phase 1/2 development for HR+/HER2- metastatic breast cancer. The acquisition is notable for what it signals internally: Novartis already sells Piqray (alpelisib), an approved PI3Kα inhibitor for the same indication. SNV4818 is designed as a direct successor with a meaningfully better side-effect profile